02-01-2021 09:06 AM | Source: SPA Securities Ltd
Key News Dabur India, Sun Pharmaceuticals & ICICI Bank Ltd by SPA Securities
News By Tags | #23 #21 #1126 #3120 #572

Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel

https://t.me/InvestmentGuruIndiacom

Download Telegram App before Joining the Channel

Key News

Dabur India PAT up 24% to Rs 494 cr in Q3, operating revenue rises 16%

Fast moving consumer goods (FMCG) major Dabur India reported a 23.7 percent year-on-year jump in net profit for the October-December quarter. The firm's profit after tax (PAT) rose to Rs 494 crore from Rs 399 crore during the corresponding quarter previous year. Dabur's operating revenue recorded a healthy 16 percent yoy growth to Rs 2729 crore - up from Rs 2353 crore - backed by a strong volume uptake. During the quarter, it reported a 18 percent surge in its volume offtake.

 

Sun Pharma Q3 PAT doubles to Rs 1,852 cr, rides on record quarterly revenue

Sun Pharmaceuticals posted a 9.2 percent year on year rise in consolidated sales from operations in the December quarter to Rs 8,782 crore, the highest ever quarterly sales posted by the company, while its net profit grew by 102.8 per cent to Rs 1,852 crore. The India sales grew by 9.4 per cent to Rs 2,753 crore while the US finished dosage sales came in at $374 mn, up 7 per cent YoY. The Ebitda was up 36.3 per cent over last year same period to Rs 2,351 crore with a resulting Ebitda margin of 26.8 per cent.

 

ICICI Bank's Q3 net profit increases 17% to Rs 5,498 crore

ICICI Bank on Saturday reported a 17.73 per cent jump in its December quarter consolidated net profit at Rs 5,498.15 crore, as against Rs 4,670.10 crore in the year-ago period. On a standalone basis, the country's second largest private sector lender by assets showed a 19.12 per cent rise in the post-tax profit at Rs 4,939.59 crore for the reporting quarter, up from Rs 4.146.46 crore in the October-December 2019 period. Its total income increased to Rs 24,416 crore from the year-ago's Rs 23,638 crore, while the total expenditure was lower at Rs 15,596 crore as against Rs 16,089 crore.

 

Dr Reddy's reports Q3 profit of Rs 20 crore, revenues at Rs 4,930 crore

DRL on Friday reported a consolidated net profit of Rs 20 crore in the third quarter against a loss of Rs 569.7 crore in the year-before period. DRL said the Q3 results were impacted primarily due the non-recognition of deferred tax assets on impairment. The firm posted a 12 per cent year-onyear growth in revenues to Rs 4,930 crore and a 10 per cent YoY growth in Ebitda to Rs 1,185 crore while the Ebitda margin stood at 24 per cent. The US business grew by 9 per cent YoY to Rs 1,739 crore while India posted an increase by 26 per cent YoY to Rs 959 crore

 

Cipla's net profit zooms 113% in December quarter; revenue up 18%

Mumbai-headquartered Cipla on Friday reported an 18 per cent increase in revenue from operations while its profit after tax more than doubled in the December quarter, on the back of growth in India and emerging markets. The total revenue from operations came in at Rs 5,169 crore and the net profit stood at Rs 748 crore, up 113 per cent. Its Ebitda stood at Rs 1,281 crore, up 69 per cent with a resulting Ebitda margin of 24.8 per cent. Kedar Upadhye, global CFO, Cipla, attributed the growth in profit to performance in across geographies, focussed cost control measures. “There has also been a benefit from the settlement that the company signed for Lenalidomide litigation ins US.”

 

Tech Mahindra profit rises 14% to Rs 1,310 crore in December quarter

IT services firm Tech Mahindra on Friday said its profit after tax rose 14.3 per cent to Rs 1,309.8 crore for the quarter ended December 31, 2020. The rise in profit was 23 per cent on a sequential basis. It said its revenue from operations was almost flat on an annual basis, and rose 2.9 per cent quarterly at Rs 9,647.1 crore in the third quarter. Margin during the quarter was 19.6 per cent, up 140 basis points quarter-on-quarter.

 

To Read Complete Report & Disclaimer Click Here

 

Above views are of the author and not of the website kindly read disclaimer